(SNDX) Syndax Pharmaceuticals - Overview

Sector: HealthcareIndustry: Biotechnology | Exchange NASDAQ (USA) | Currency USD | Market Cap: 2.119m | Total Return 91.2% in 12m

Stock: Cancer Therapies, Leukemia Treatment, Antibody Therapy

Total Rating 35
Risk 22
Buy Signal -0.76
Biotechnology -5.1
Biotechnology -4.3
Market Cap: 2,119m
Avg Trading Vol: 30.7M USD
ATR: 4.61%
Peers RS (IBD): 55.8
Risk 5d forecast
Volatility 56.0%
Relative Tail Risk -10.8%
Reward TTM
Sharpe Ratio 1.09
Alpha 67.51
Character TTM
Beta 0.836
Beta Downside 2.271
Drawdowns 3y
Max DD 64.81%
CAGR/Max DD 0.06

EPS (Earnings per Share)

EPS (Earnings per Share) of SNDX over the last years for every Quarter: "2021-03": -0.54, "2021-06": -0.44, "2021-09": -0.4, "2021-12": 1.81, "2022-03": -0.63, "2022-06": -0.62, "2022-09": -0.58, "2022-12": -0.62, "2023-03": -0.59, "2023-06": -0.64, "2023-09": -0.73, "2023-12": -1, "2024-03": -0.85, "2024-06": -0.8, "2024-09": -0.98, "2024-12": -1.1, "2025-03": -0.9846, "2025-06": -0.83, "2025-09": -0.7, "2025-12": -0.78,
EPS CAGR: -8.22%
EPS Trend: -62.8%
Last SUE: -0.54
Qual. Beats: 0

Revenue

Revenue of SNDX over the last years for every Quarter: 2021-03: 0.379, 2021-06: 0.379, 2021-09: 12.375, 2021-12: 126.576, 2022-03: 0, 2022-06: 0, 2022-09: 0, 2022-12: 0, 2023-03: 0, 2023-06: 0, 2023-09: 0, 2023-12: 0.536, 2024-03: 0, 2024-06: 3.5, 2024-09: 12.5, 2024-12: 7.68, 2025-03: 20.042, 2025-06: 37.958, 2025-09: 45.871, 2025-12: 68.481,
Rev. CAGR: 710.39%
Rev. Trend: 91.2%
Last SUE: 0.13
Qual. Beats: 0

Description: SNDX Syndax Pharmaceuticals March 04, 2026

Syndax Pharmaceuticals, Inc. (SNDX) is a biopharmaceutical company focused on cancer therapies. The company is developing Revumenib for relapsed/refractory acute leukemia and Niktimvo for chronic graft-versus-host disease. The biotechnology sector is characterized by high research and development costs and a lengthy drug approval process.

Additional pipeline candidates include Revumenib for acute myeloid leukemia and metastatic colorectal cancer, Axatilimab for idiopathic pulmonary fibrosis, and Entinostat, a Class 1 HDAC inhibitor. Syndax has a licensing agreement with Eddingpharm International for Entinostat. Understanding the pipeline and market potential of these drugs is key to evaluating the companys future. For further analysis of SNDXs drug pipeline and market opportunities, explore ValueRay.

Headlines to watch out for

  • Revuforj approval and sales drive revenue growth
  • Niktimvo commercialization expands product portfolio
  • Clinical trial results impact future drug development
  • Regulatory approvals crucial for pipeline progression
  • Competition from other cancer therapies affects market share

Piotroski VR‑10 (Strict, 0-10) 0.5

Net Income: -285.4m TTM > 0 and > 6% of Revenue
FCF/TA: -0.61 > 0.02 and ΔFCF/TA -23.08 > 1.0
NWC/Revenue: 236.7% < 20% (prev 2.11k%; Δ -1.87k% < -1%)
CFO/TA -0.61 > 3% & CFO -323.0m > Net Income -285.4m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 4.40 > 1.5 & < 3
Outstanding Shares: last quarter (86.6m) vs 12m ago 0.97% < -2%
Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin)
Asset Turnover: 27.48% > 50% (prev 3.27%; Δ 24.21% > 0%)
Interest Coverage Ratio: -2.32 > 6 (EBITDA TTM -220.8m / Interest Expense TTM 71.6m)

Altman Z'' -9.40

A: 0.77 (Total Current Assets 528.1m - Total Current Liabilities 120.1m) / Total Assets 529.7m
B: -2.84 (Retained Earnings -1.51b / Total Assets 529.7m)
C: -0.26 (EBIT TTM -165.9m / Avg Total Assets 627.3m)
D: -3.24 (Book Value of Equity -1.51b / Total Liabilities 465.1m)
Altman-Z'' Score: -9.40 = D

Beneish M 0.44

DSRI: 0.38 (Receivables 38.0m/13.9m, Revenue 172.4m/23.7m)
GMI: 1.00 (fallback, negative margins)
AQI: 0.00 (AQ_t 0.00 / AQ_t-1 0.17)
SGI: 7.28 (Revenue 172.4m / 23.7m)
TATA: 0.07 (NI -285.4m - CFO -323.0m) / TA 529.7m)
Beneish M-Score: 0.44 (Cap -4..+1) = D

What is the price of SNDX shares?

As of March 30, 2026, the stock is trading at USD 23.49 with a total of 1,193,930 shares traded.
Over the past week, the price has changed by -2.49%, over one month by +8.20%, over three months by +11.49% and over the past year by +91.21%.

Is SNDX a buy, sell or hold?

Syndax Pharmaceuticals has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy SNDX.
  • StrongBuy: 9
  • Buy: 2
  • Hold: 1
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the SNDX price?

Issuer Target Up/Down from current
Wallstreet Target Price 39.2 66.8%
Analysts Target Price 39.2 66.8%

SNDX Fundamental Data Overview March 26, 2026

P/S = 12.2922
P/B = 33.094
Revenue TTM = 172.4m USD
EBIT TTM = -165.9m USD
EBITDA TTM = -220.8m USD
Long Term Debt = 343.9m USD (from longTermDebt, last quarter)
Short Term Debt = 472k USD (from shortTermDebt, last quarter)
Debt = 346.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 211.6m USD (from netDebt column, last quarter)
Enterprise Value = 2.07b USD (2.12b + Debt 346.5m - CCE 394.1m)
Interest Coverage Ratio = -2.32 (Ebit TTM -165.9m / Interest Expense TTM 71.6m)
EV/FCF = -6.41x (Enterprise Value 2.07b / FCF TTM -323.2m)
FCF Yield = -15.60% (FCF TTM -323.2m / Enterprise Value 2.07b)
FCF Margin = -187.5% (FCF TTM -323.2m / Revenue TTM 172.4m)
Net Margin = -165.6% (Net Income TTM -285.4m / Revenue TTM 172.4m)
Gross Margin = unknown ((Revenue TTM 172.4m - Cost of Revenue TTM 6.97m) / Revenue TTM)
Tobins Q-Ratio = 3.91 (Enterprise Value 2.07b / Total Assets 529.7m)
Interest Expense / Debt = 15.21% (Interest Expense 52.7m / Debt 346.5m)
Taxrate = 21.0% (US default 21%)
NOPAT = -131.1m (EBIT -165.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.40 (Total Current Assets 528.1m / Total Current Liabilities 120.1m)
Debt / Equity = 5.36 (Debt 346.5m / totalStockholderEquity, last quarter 64.6m)
Debt / EBITDA = -0.96 (negative EBITDA) (Net Debt 211.6m / EBITDA -220.8m)
Debt / FCF = -0.65 (negative FCF - burning cash) (Net Debt 211.6m / FCF TTM -323.2m)
Total Stockholder Equity = 138.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -45.50% (Net Income -285.4m / Total Assets 529.7m)
RoE = -206.6% (Net Income TTM -285.4m / Total Stockholder Equity 138.1m)
RoCE = -34.42% (EBIT -165.9m / Capital Employed (Equity 138.1m + L.T.Debt 343.9m))
RoIC = -58.48% (negative operating profit) (NOPAT -131.1m / Invested Capital 224.1m)
WACC = 9.36% (E(2.12b)/V(2.47b) * Re(8.92%) + D(346.5m)/V(2.47b) * Rd(15.21%) * (1-Tc(0.21)))
Discount Rate = 8.92% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 9.29%
[DCF] Fair Price = unknown (Cash Flow -323.2m)
EPS Correlation: -62.85 | EPS CAGR: -8.22% | SUE: -0.54 | # QB: 0
Revenue Correlation: 91.18 | Revenue CAGR: 710.4% | SUE: 0.13 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-0.45 | Chg7d=+0.016 | Chg30d=+0.030 | Revisions Net=+0 | Analysts=8
EPS current Year (2026-12-31): EPS=-1.54 | Chg7d=+0.056 | Chg30d=+0.004 | Revisions Net=-3 | Growth EPS=+53.3% | Growth Revenue=+110.9%
EPS next Year (2027-12-31): EPS=-0.16 | Chg7d=-0.013 | Chg30d=-0.253 | Revisions Net=+1 | Growth EPS=+89.7% | Growth Revenue=+51.1%
[Analyst] Revisions Ratio: +0.00 (1 Up / 1 Down within 30d for Next Quarter)

Additional Sources for SNDX Stock

Fund Manager Positions: Dataroma | Stockcircle